Literature DB >> 9310332

Fgfr2 and osteopontin domains in the developing skull vault are mutually exclusive and can be altered by locally applied FGF2.

S Iseki1, A O Wilkie, J K Heath, T Ishimaru, K Eto, G M Morriss-Kay.   

Abstract

Mutations in the human fibroblast growth factor receptor type 2 (FGFR2) gene cause craniosynostosis, particularly affecting the coronal suture. We show here that, in the fetal mouse skull vault, Fgfr2 transcripts are most abundant at the periphery of the membrane bones; they are mutually exclusive with those of osteopontin (an early marker of osteogenic differentiation) but coincide with sites of rapid cell proliferation. Fibroblast growth factor type 2 (FGF2) protein, which has a high affinity for the FGFR2 splice variant associated with craniosynostosis, is locally abundant; immunohistochemical detection showed it to be present at low levels in Fgfr2 expression domains and at high levels in differentiated areas. Implantation of FGF2-soaked beads onto the fetal coronal suture by ex utero surgery resulted in ectopic osteopontin expression, encircled by Fgfr2 expression, after 48 hours. We suggest that increased FGF/FGFR signalling in the developing skull, whether due to FGFR2 mutation or to ectopic FGF2, shifts the cell proliferation/differentiation balance towards differentiation by enhancing the normal paracrine down-regulation of Fgfr2.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9310332     DOI: 10.1242/dev.124.17.3375

Source DB:  PubMed          Journal:  Development        ISSN: 0950-1991            Impact factor:   6.868


  41 in total

Review 1.  Derivation of the mammalian skull vault.

Authors:  G M Morriss-Kay
Journal:  J Anat       Date:  2001 Jul-Aug       Impact factor: 2.610

2.  Mesodermal expression of Fgfr2S252W is necessary and sufficient to induce craniosynostosis in a mouse model of Apert syndrome.

Authors:  Greg Holmes; Claudio Basilico
Journal:  Dev Biol       Date:  2012-06-01       Impact factor: 3.582

3.  A splicing switch and gain-of-function mutation in FgfR2-IIIc hemizygotes causes Apert/Pfeiffer-syndrome-like phenotypes.

Authors:  M K Hajihosseini; S Wilson; L De Moerlooze; C Dickson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

4.  Alx4 and Msx2 play phenotypically similar and additive roles in skull vault differentiation.

Authors:  Ileana Antonopoulou; Lampros A Mavrogiannis; Andrew O M Wilkie; Gillian M Morriss-Kay
Journal:  J Anat       Date:  2004-06       Impact factor: 2.610

5.  Homodimerization controls the fibroblast growth factor 9 subfamily's receptor binding and heparan sulfate-dependent diffusion in the extracellular matrix.

Authors:  Juliya Kalinina; Sara A Byron; Helen P Makarenkova; Shaun K Olsen; Anna V Eliseenkova; William J Larochelle; Mohanraj Dhanabal; Steven Blais; David M Ornitz; Loren A Day; Thomas A Neubert; Pamela M Pollock; Moosa Mohammadi
Journal:  Mol Cell Biol       Date:  2009-06-29       Impact factor: 4.272

Review 6.  FGFR4: A promising therapeutic target for breast cancer and other solid tumors.

Authors:  Kevin M Levine; Kai Ding; Lyuqin Chen; Steffi Oesterreich
Journal:  Pharmacol Ther       Date:  2020-05-31       Impact factor: 12.310

Review 7.  Hand in glove: brain and skull in development and dysmorphogenesis.

Authors:  Joan T Richtsmeier; Kevin Flaherty
Journal:  Acta Neuropathol       Date:  2013-03-23       Impact factor: 17.088

8.  De novo alu-element insertions in FGFR2 identify a distinct pathological basis for Apert syndrome.

Authors:  M Oldridge; E H Zackai; D M McDonald-McGinn; S Iseki; G M Morriss-Kay; S R Twigg; D Johnson; S A Wall; W Jiang; C Theda; E W Jabs; A O Wilkie
Journal:  Am J Hum Genet       Date:  1999-02       Impact factor: 11.025

9.  FGF9 monomer-dimer equilibrium regulates extracellular matrix affinity and tissue diffusion.

Authors:  Masayo Harada; Hirotaka Murakami; Akihiko Okawa; Noriaki Okimoto; Shuichi Hiraoka; Taka Nakahara; Ryogo Akasaka; Yo-Ichi Shiraishi; Noriyuki Futatsugi; Yoko Mizutani-Koseki; Atsushi Kuroiwa; Mikako Shirouzu; Shigeyuki Yokoyama; Makoto Taiji; Sachiko Iseki; David M Ornitz; Haruhiko Koseki
Journal:  Nat Genet       Date:  2009-02-15       Impact factor: 38.330

10.  Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(+P253R) mice.

Authors:  Yingli Wang; Miao Sun; Victoria L Uhlhorn; Xueyan Zhou; Inga Peter; Neus Martinez-Abadias; Cheryl A Hill; Christopher J Percival; Joan T Richtsmeier; David L Huso; Ethylin Wang Jabs
Journal:  BMC Dev Biol       Date:  2010-02-22       Impact factor: 1.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.